Investor Presentaiton slide image

Investor Presentaiton

TIGIT Bispecific DGK Inhibitor AR LDD Oncology Opdivo Opdualag AR LDD phase 1 design in 1L & 2L mCRPC Key eligibility criteria • • Open label¹: Assess the safety, tolerability and preliminary efficacy Histologically or cytologically confirmed adenocarcinoma of the prostate Progressed on ADT and ≥ 1 prior secondary hormonal therapy approved for CRPC ECOG performance status (PS) 0 or 1 Dose escalation/Dose expansion Primary endpoint Safety and tolerability Key secondary endpoints: Confirmed Prostate Specific Antigen (PSA) decline of ≥ 50% from baseline (PSA50) Objective soft tissue response (CR or PR), DOR, rPFS, PSA PFS Part A Dose escalation Part B Dose expansion to optimize RP2D Data anticipated in 2024 Ill Bristol Myers Squibb™ 1. NCT04428788 Not for Product Promotional Use 105
View entire presentation